[Comment] Biomarkers for juvenile idiopathic arthritis treatment response—have we identified them?

Serum biomarkers have increasingly been studied to aid in the diagnosis, prognosis, disease monitoring, and treatment response in patients with juvenile idiopathic arthritis (JIA). One might think that by now we would have found biomarkers for diagnosis and treatment. Ideally, a biomarker that can assist in deciding which treatment would be effective for which patients. However, in 2025, JIA remains a clinical diagnosis, taking into account presenting symptoms, imaging findings, and blood test results (such as rheumatoid factor and antinuclear antibodies).